ATEC | Ticker Profile - Titan Protect

ATEC

Alphatec Holdings, Inc.

Healthcare · Medical Devices · NMS

$8.00

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.2B

Total market value of the company

Trailing P/E

N/A

Forward P/E

13.60

Based on estimated future earnings — lower means cheaper

Rev Growth

+13.6%

Year-over-year revenue change

Profit Margin

-15.9%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$16.00

+100% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 12 analysts covering this stock

About Alphatec Holdings, Inc.

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissue; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. The company was founded in 1990 and is headquartered in Carlsbad, California.

https://www.atecspine.com

Country: United States Employees: 913 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.189

Positive but modest risk-adjusted returns

Kelly Fraction

0.0061

Marginal edge — very small allocation suggested

Calmar Ratio

-0.177

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-12.3%

Historical annualised return based on price data

Max Drawdown

-69.2%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.97

Less volatile than the market — more defensive

52W High

$23.29

66% below the year high

52W Low

$6.82

17% above the year low

Avg Volume

3,236,016

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

10.7%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.83

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

3,303.35

Heavy leverage — higher financial risk if revenues decline

Current Ratio

1.90

Healthy liquidity position

Quick Ratio

1.05

Like current ratio but excludes inventory — stricter test

Gross Margin

70.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-11.5%

Profit from core operations before interest and tax

Free Cash Flow

$55M

Positive — the business generates more cash than it spends

Revenue (TTM)

$787M

Total revenue over the last 12 months

Net Income

$-125,357,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$24.00

Target Median

$16.00

Target Low

$11.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go